Novo Nordisk's bid to supply diabetes sufferers a much less burdensome dosing routine has suffered a setback. The FDA has rejected the corporate's utility for icodec, a slow-release insulin the corporate designed for once-weekly dosing as an alternative choice to day by day insulin injections. Novo Nordisk stated the FDA's full response letter raised questions concerning the manufacturing course of […]
